In the last trading session, 17,521,999 shares of the Iterum Therapeutics plc(NASDAQ:ITRM) were traded, and its beta was 0. Most recently the company’s share price was $2.03, and it changed around -$0.04 or -0.02% from the last close, which brings the market valuation of the company to $309.6 Million. ITRM currently trades at a discount to its 52-week high of $6.02, offering almost -196.55% off that amount. The share price’s 52-week low was $0.451, which indicates that the current value has risen by an impressive 77.78% since then. We note from Iterum Therapeutics plc’s average daily trading volume that its 10-day average is 40.34 Million shares, with the 3-month average coming to 22.73 Million.
Iterum Therapeutics plc stock received a consensus recommendation rating of Underweight, based on a mean score of 3.2. If we narrow it down even further, the data shows that 1 out of 4 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, 3 recommended ITRM as a Hold, whereas none deemed it a Buy, and no one rated it as Underweight. Iterum Therapeutics plc is expected to report earnings per share of -$0.19 for the current quarter.
Iterum Therapeutics plc (NASDAQ:ITRM): Trading Information
Although ITRM has showed a red trend with a performance of -1.93% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $2.34- on Wednesday, Feb 17 increased the stock’s daily price by 13.25%. The company’s shares are currently up 1.05% year-to-date, but still down -0.1018 over the last five days. On the other hand, Iterum Therapeutics plc (NASDAQ:ITRM) is 0.07% up in the 30-day period. We can see from the shorts that 1.84 Million shares have been sold at a short interest cover period of 0.08 day(s).
The consensus price target as assigned by Wall Street analysts is $1.5, which translates to bears needing to reduce their stock price by -26.11% from its current value. Analyst projections state that ITRM is forecast to be at a low of $1 and a high of $2. In order for the stock price to hit the forecast high, the stock would need to surge -1.48% from its current level, while the stock would need to crash -50.74% from its current level to reach the projected low.
Iterum Therapeutics plc (ITRM) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%. Iterum Therapeutics plc earnings are expected to decrease by -32.4% in 2021, but the outlook is negative 0% per year for the next five years.
Iterum Therapeutics plc (NASDAQ:ITRM)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 1.15% of Iterum Therapeutics plc shares, and 34.21% of them are in the hands of institutional investors. The stock currently has a share float of 34.61%. Iterum Therapeutics plc stock is held by 22 institutions, with Canaan Partners X LLC being the largest institutional investor. By Dec 30, 2020, it held 1.43% of the shares, which is about 1.73 Million shares worth $1.71 Million.
Frazier Management LLC, with 1.27% or 1.54 Million shares worth $1.52 Million as of Dec 30, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.